Citigroup Upgrades Travere Therapeutics to Buy, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Carly Kenselaar has upgraded Travere Therapeutics (NASDAQ:TVTX) from Neutral to Buy and increased the price target from $7 to $10.
December 05, 2023 | 12:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup upgraded Travere Therapeutics to Buy and raised the price target to $10, indicating a positive outlook on the stock.
Upgrades by analysts, especially from neutral to buy, typically suggest a bullish view on the stock and can lead to increased investor confidence and a potential rise in the stock price in the short term. The increase in the price target further reinforces the positive sentiment.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100